Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office has issued a notice of allowance for TapImmune's US patent application related to methods for enhancing the cytotoxic T-lymphocyte response to tumor cells by introducing the transporters associated with antigen processing, or TAP, molecule into the infected cell.
Subscribe to our email newsletter
TAP molecules are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.
Denis Corin, CEO of TapImmune, said: “This is a tremendous milestone for the company. The notice of allowance for this patent gives our company a well-protected platform from which to continue our development on a number of potential products in both the prophylactic and therapeutic vaccine markets and will allow us to approach potential partners with confidence.”